IAIM
CRSP icon

International Assets Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

International Assets Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-827
Closed -$38.9K – 1043
2024
Q3 		$38.9K Buy
+827
New +$42K ﹤0.01% 1151
2021
Q2 		– Sell
-80
Closed -$12K – 786
2021
Q1 		$12K Hold
80
– – ﹤0.01% 1488
2020
Q4 		$12K Buy
+80
New +$9.46K ﹤0.01% 1349

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

International Assets Investment Management's CRSP Position: Q4 2024 in Review

International Assets Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 827 shares — an estimated $38.9K sold.

International Assets Investment Management first reported a position in CRSP in Q4 2020 and held it in 3 quarters. The position peaked at $38.9K in Q3 2024. 406 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • International Assets Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • International Assets Investment Management sold 827 CRISPR Therapeutics shares in Q4 2024, an estimated $38.9K.
  • International Assets Investment Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 3 quarters.
  • International Assets Investment Management's CRISPR Therapeutics position peaked at $38.9K in Q3 2024.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on International Assets Investment Management's 13F filing for Q4 2024, filed 8 Jan 2025.